Kornimate/medical-research-clean huggingface dataset:
family functioning and child behavior when a sibling is critically ill

Conditions: Child Behavior

Summary: the goal of this study is to determine if there is a correlation between an efficacious family environment and sibling behavior in families with children who are critically ill.

families of critically ill children can face many emotional challenges during the course of a child's illness. while some research has looked at the impact on parents, there has been little focused on siblings. we want to better understand how social support may have a protective effect on siblings' quality of life. the goal of this study is to determine if there is a correlation between an efficacious family environment and sibling behavior in families with children who are critically ill. our hypothesis is that a cohesive, emotionally rich and open family environment provides social support so that siblings can explore and express the difficult emotions that accompany illness, and is therefore a protective factor for a sibling's behavior.

Eligibility criteria:
inclusion criteria: * adult (age 18 and older) who has decision making authority for chop patient who has been referred to the pediatric advanced care team (pact) for palliative care services, and with a child(ren) age 6-11 years who is a sibling of the patient * any race/ethnicity exclusion criteria: * non-english speaking

Keywords: siblings family child behavior critical illness social support
the constitution and efficacy of chinese medicine of infertility male, female, and pregnant female

Conditions: Infertility; Miscarriage Threatening

Summary: the project aims to conduct a retrospective study to assess the impact of traditional chinese medicine (tcm) on improving pregnancy rates and preventing miscarriages. it will include patients with infertility issues or a history of miscarriage. the study will analyze demographic and physiological data, tcm constitution, basal body temperature, reproductive history for females, and semen analysis for males, to determine the effectiveness of tcm care in enhancing fertility outcomes.

the present project plans to conduct a retrospective study based on the data of the national health insurance traditional chinese medicine enhancement quality of maternity care plan. analysis methods: the collected data was archived using spss software, and the following testing methods were employed for statistical analysis among different datasets: 1. paired-t test: examining differences in temperature and duration between follicular and luteal phases in females before and after treatment. 2. chi-square test: assessing the relationship between traditional chinese medicine constitution and pregnancy outcomes. 3. mcnemar test: testing the significance of changes in traditional chinese medicine constitution before and after treatment. 4. logistic regression: conducting multivariate analysis to explore factors associated with pregnancy status. the purpose of this project is to figure out after conducting proper chinese medical care, whether it will improve the target patients' pregnancy rate and miscarriage prevention rate. those data will conduct a biological analysis to compare the difference between pregnancy and miscarriage prevention rates between different patients.

Eligibility criteria:
inclusion criteria: * fertility assistance: for male and female patients who have been married for over a year with regular sexual activity but are unable to conceive. * miscarriage prevention: for females who have had miscarriages, non-natural conception, conception through fertility assistance, and are prone to miscarriage. exclusion criteria: * fertility assistance: 1. incomplete demographic data for males/females 2. incomplete traditional chinese medicine constitution determination data for males/females 3. incomplete information on the follicular/luteal phase for females 4. incomplete semen analysis data for males * miscarriage prevention: 1. incomplete demographic data 2. incomplete physiological examination data 3. incomplete data on related disease records

Keywords: infertility chinese medicine miscarriage prevention retrospective study
severity of fecal incontinence and manometric values using the anopress® device in women

Conditions: Fecal Incontinence; Anal; Sphincter, Incontinence; Incontinence, Urge

Summary: the purpose of this study is to stablish a correlation between fecal incontinence severity scales (wexner \& st. mark's) and manometric values obtained using the anopress® portable manometry and values obtained using endoanal ultrasound in women with fecal incontinence.

the anopress® portable anal manometry will be used to measure the pressures of the anal canal in different phases: rest, squeeze, strain and endurance. all female patients referred with the diagnosis of fecal incontinence giving written informed consent will undergo a endoanal portable manometry at our outpatients clinics. they will be asked to fill out the severity questionaries (sant mark's and wexner). all data will be collected for analysis. an endoanal ultrasound will be performed in all patients to assess the sphincter integrity.

Eligibility criteria:
inclusion criteria: * patients with the clinical diagnosis of fecal incontinence * age ≥ 18 years. * informed consent signed by the patient and the researcher. exclusion criteria: * patients with psychiatric illnesses, addictions or any disorder that prevents understanding of the study. * inability to read or understand the questionnaires. * inability to read or understand any of the informed consent languages (catalan, spanish). * any patient who, due to his medical characteristics, presents a high individual risk when being included and completing the study.

Keywords: anal manometry anal portable manometry fecal incontinence severity endoanal ultrasound
involvement of reticulum endoplasmic stress in the physiopathology of polycystic ovary syndrome

Conditions: Polycystic Ovary Syndrome

Summary: the main objective of the present project is to evaluate the relevance of reticulum stress in the pathogenesis of polycystic ovary syndrome (pcos), focusing particularly on the underlying mechanisms of insulin resistance, which is the origin of metabolic comorbidities. furthermore, the investigators will assess the potential of insulin sensitizers as a treatment to control endoplasmic reticulum stress markers in pcos patients.

to do this, the investigators will evaluate anthropometric, biochemical and hormone parameters, lipid profile and cardiovascular risk markers (using enzymatic and biochemical techniques, nephelometry, enzyme-linked immunosorbent assay, radioimmunoassay), and markers of endoplasmic reticulum stress and the insulin pathway and inflammatory and apoptotic parameters (by means of western blot, real time- polymerase chain reaction (rt-pcr), luminex® xmap® technology ) in patients with and without pcos. the investigators' second objective is to evaluate (using the abovementioned methodology) the efficacy of different insulin sensitizers (myoinositol and metformin) administered to pcos patients during a 3-month period after which the investigators will analyze different parameters of oxidative stress and mitochondrial function (using clark electrode and fluorometric techniques).

Eligibility criteria:
inclusion criteria: * women diagnosed with pcos using the rotterdam criteria * women of reproductive age exclusion criteria: * organic, malignant, haematological, infectious or inflammatory disease * history of ischaemic heart disease (stroke or thromboembolism) * diabetes mellitus, * secondary causes of obesity (hypothyroidism, cushing's syndrome) * severe hypertension. * smoking or alcohol habit

Keywords: reticulum endoplasmic stress polycystic ovary syndrome mitochondrial function insulin resistance inflammation myoinositol metformin oxidative stress
an efficacy and safety study of bimatoprost 0.01% alone compared with travoprost 0.004% and timolol 0.5% in subjects with glaucoma or ocular hypertension

Conditions: Glaucoma; Ocular Hypertension

Summary: this efficacy and safety study will evaluate lumigan® rc/ lumigan® .01 (bimatoprost 0.01%) alone compared to travatan z® (travoprost 0.004%) and timolol maleate-ex, 0.5%/timolol gfs 0.5% (timolol 0.5% ophthalmic gel forming solution) in patients who require iop lowering therapy.


Eligibility criteria:
inclusion criteria: * ocular hypertension or glaucoma that requires treatment with medication * have a best corrected visual acuity (bcva) of 20/100 or better in both eyes exclusion criteria: * history of lasik, lasek, rk, and/or prk in the study eye(s) * history of any intraocular surgery or glaucoma laser surgery in the study eye(s) within 3 months * use of topical, periorbital, intravitreal or systemic steroid within 3 months or expected use during the course of study
a study to investigate a clostridium difficile vaccine in healthy adults aged 50 to 85 years, who will each receive 3 doses of vaccine.

Conditions: Clostridium Difficile

Summary: this study will investigate a clostridium difficile vaccine in healthy adults aged 50 to 85 years, who will each receive 3 doses of vaccine. subjects will receive their vaccine doses at either months 0, 1, and 3 or days 1, 8, and 30. subjects will be divided into 2 age groups (50-64 and 65-85 years of age). the study will assess how safe and tolerable the vaccine is, and also look at subjects' immune response to the vaccine.


Eligibility criteria:
inclusion criteria: * healthy male and female adults aged 50 to 85 years at enrollment exclusion criteria: * proven or suspected prior episode of clostridium difficile associated diarrhea. * unstable chronic medical condition or disease requiring significant change in therapy or hospitalization for worsening disease within 8 weeks before receipt of study vaccine. * any contraindication to vaccination or vaccine components, including previous anaphylactic reaction to any vaccine or vaccine-related components
study about the effect of doxycycline and acetylcystein in the treatment of cd-associated fistulae

Conditions: Crohn's Disease

Summary: the investigators will study whether local instillation of doxycycline and acetylcystein results in fistula closure in cd patients.


Eligibility criteria:
inclusion criteria: * fistulizing cd * cd \< 6 months * at least one insufficient fistula closure try exclusion criteria: * cdai \> 200 * abscesses * crp \> 100
tips for variceal rebleeding in cirrhotic patients with occlusive portal vein thrombosis and ctpv

Conditions: Portal Vein, Cavernous Transformation of; Portal Vein Thrombosis; Liver Cirrhosis; Bleeding Esophageal Varices

Summary: to date, there is no treatment strategies for these patients according to american association of the study of liver disease (aasld) practice guidelines and baveno v consensus. thus, we aim to compare the safety and efficacy of tips and conservative treatment (non-selective beta blockers, endoscopic therapy and/or anticoagulation) in patients with pvt and cptv.

the incidence of portal vein thrombosis (pvt) is about 16% in cirrhotic patients. chronic pvt often cause two main undesirable consequences: symptomatic portal hypertension (such as variceal bleeding or ascites) and cavernous transformation of portal vein (cptv). the former could lead to death and the latter increases the difficulty of the transjugular intrahepatic portosystemic shunt (tips) treatment, which is considered as a main effective treatment for symptomatic portal hypertension. some patients with cptv and variceal bleeding only have to receive conservative treatment (non-selective beta blockers, endoscopic therapy and/or anticoagulation). with advances in technology, modified tips procedure could significantly improve the operation success rate of patients with cptv. to date, the difference in safety and efficacy between tips and conservative treatment (non-selective beta blockers, endoscopic therapy and/or anticoagulation) in patients with pvt and cptv is still unclear.

Eligibility criteria:
inclusion criteria: * all patients diagnosis with portal vein thrombosis and cavernous transformation of portal vein and portal hypertension by contrast enhanced ct or mri. * history of variceal bleeding. * liver cirrhosis. * neutrophilous counts≥ 1.5×109/l, platelet counts ≥ 50 × 109/l, hemoglobin≥ 85g/l. * albumin ≥2.8 g/dl, total bilirubin \<51.3 umol/l; alanine aminotransferase (alt) and aspartate transaminase（ast）\<5 times of upper limit. * pt(prothrombin time)-inr(international normalized ratio) \< 1.7. exclusion criteria: * thrombosis involve superior mesenteric vein, splenic vein, or the whole portal vein system. not suitable for tips (judged by principal investigator). * company with malignant tumors in liver or other organs. * patients with known severe dysfunction of heart, lung, brain or kidney. * active bleeding. * not eligible for anticoagulation therapy,non-selective beta blockers or endoscopic therapy. * uncontrolled infection. * pregnancy and breastfeeding. * hiv infection.
study to investigate if the uptake of ticagrelor into the body differs depending on method of administration.

Conditions: Bioavailability Heathy Volunteers

Summary: study to investigate if the uptake of ticagrelor into the body differs depending on method of administration.

study to evaluate the bioavailability of the crushed ticagrelor tablets when administered orally or through nasogastric tubes compared to whole ticagrelor tablets given orally

Eligibility criteria:
inclusion criteria: * healthy male and female volunteers aged 18 to 50 years (inclusive) with suitable veins for cannulation or repeated venepuncture * have a body mass index between 18 and 30 kg/m2 (inclusive) and weigh at least 50 kg (110 pounds \[lbs\]) and no more than 100 kg (220 lbs). * provision of signed and dated, written informed consent prior to any study specific procedures exclusion criteria: * history of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate in the study * history of haemophilia, von willebrand's disease, lupus anticoagulant or other diseases/syndromes that can either alter or increase the propensity for bleeding * a personal history of vascular abnormalities including aneurysms; a personal history of severe haemorrhage, haematemesis, melena, haemoptysis, severe epistaxis, severe thrombocytopenia, intracranial haemorrhage; or rectal bleeding within 3 months prior to the screeening visit; or history suggestive of peptic ulcer disease * history of frequent and/or significant nose bleed or clinically significant non traumatic bleed, bruise/haematoma or any other clinically significant bleeding risk, as judged by the investigator

Keywords: phase 1, pharmacokinetic, safety, ticagrelor
fish oil supplementation during pregnancy for prevention of asthma, eczema and allergies in childhood

Conditions: Asthma; Eczema; Allergy

Summary: the aim of this study is to prevent asthma and allergies in childhood by supplementation with fish oil (n-3 fatty acids) to the mother during pregnancy. paticipants are mother and children participating in the abc-(asthma begins in childhood)cohort. mothers are recruited during pregnancy and receive supplement with n-3 fatty acids or olive oil (placebo) from week 24 of gestation to 1 week after delivery. the child is followed with acute and planned visit at the research unit and diagnosis of disease is done in the research unit according to predefined algorithms.


Eligibility criteria:
inclusion criteria (mother): * pregnant women * living in sealand, denmark * fluent in danish language * willing to let the newborn child participate in the study exclusion criteria (mother): * participating in other clinical trial

Keywords: asthma eczema sensitization allergy
ketamine versus placebo for treatment resistant major depressive disorder

Conditions: Major Depressive Disorder

Summary: ketamine infusions resulted in an acute reduction in global depression scores and in severity of suicidal ideation. the investigators therefore plan to investigate the feasibility and efficacy of repeated intravenous administration of ketamine in severely depressed, treatment resistant patients. the results of the study could lead to development of new strategies for treating depression.


Eligibility criteria:
inclusion criteria: * outpatient with sever treatment resistant depression * currently depressed * currently under regular psychiatric care * on an aggressive antidepressant regimen, stable for 4 weeks. exclusion criteria: * no history of other major psychiatric illness, including bipolar * no history of psychosis * no history of drug abuse * no major medical illness or unstable medical problem
expression of tumor markers in circulating tumor cells of metastatic hormone-sensitive prostate cancer

Conditions: Prostate Cancer

Summary: as prostate cancer progresses, tumor cells dissociate and enter the bloodstream. considered a "liquid biopsy," these circulating tumor cells (ctc) can show how a patient's cancer evolves and responds to treatments. the purpose of this study is to determine whether sequentially analyzing the expression of tumor markers in circulating tumor cells in newly diagnosed metastatic hormone-sensitive prostate cancer patients can predict the outcome of these patients.


Eligibility criteria:
inclusion criteria: 1. male patients; 2. 18 yrs and older, and 80 yrs and younger; 3. histologically or cytologically proven prostate adenocarcinoma; 4. imaging examinations including emission computed tomography (ect),positron emission tomography (pet),computed tomography(ct)and magnetic resonance imaging (mri) revealed non-regional lymph node metastasis, bone metastasis, or visceral metastasis; 5. not yet receiving hormonal therapy; 6. not yet receiving chemotherapy previously; 7. not yet receiving radical prostatectomy, radiotherapy, or transurethral resection of the prostate (turp) previously; 8. patients are willing to participate and can be followed up regularly； exclusion criteria: 1. received radical prostatectomy, radiotherapy, or transurethral resection of the prostate (turp) previously; 2. received androgen deprivation therapy (including surgical castration, medical castration, anti-androgen therapy, and maximum androgen blockade) before inclusion; 3. patients received chemotherapy previously; 4. combined with other malignant tumor history (in addition to the skin basal cell carcinoma or other tumors that have been cured more than five years);

Keywords: metastatic hormone-sensitive prostate cancer；circulating tumor cells；prognosis；liquid biopsy
syndecan 1 as biomarker for inflammation

Conditions: Colitis

Summary: the aim of the study is to evaluate the soluble biomarker syndecan-1 (ssdc1) taken from venous blood of patients with infectious intestinal diseases such as clostridium difficile-associated colitis, bacterial colitis, norovirus enteritis and crohn´s disease or ulcerative colitis. the level of ssdc1 will be compared with disease activity in patients with active inflammation and with disease in remission. secondary objectives were the assessment of correlation of the above-mentioned factors with the crp value. subjects will be volunteers. blood will be taken as part of the routine clinical work-up after the written agreement blood and ssdc1-level will be assessed using a human-specific ssdc1 elisa assay. in addition, the subjects are asked to answer a short questionnaire. the study is designed as a prospective, comparative cohort study.


Eligibility criteria:
inclusion criteria: * subject with at least 18 years of age * able to give informed consent * healthy volunteer or inflammatory bowel condition (inflammatory bowel disease, infectious colitis) exclusion criteria: * not able to give informed consent

Keywords: ulcerative colitis clostidium difficile-associated colitis syndecan-1 biomarker
long-term outcomes of living donor liver transplantations with anti-hbc (+) grafts in pediatric patients

Conditions: Living Donor Liver Transplantations With Anti-HBc (+) Grafts

Summary: the goal of this observational study is to compare in anti-hbc (+) grafts/ anti-hbc (-) grafts. the main question it aims to answer is the long-term efficacy of active vaccination and graft/patient outcomes of anti-hbc (+) grafts have yet to be comprehensively investigated. researchers will compare anti-hbc (+) grafts/ anti-hbc (-) to see if it would affect the long-term survival.

a particular strength of the present study is in the inclusion of a consecutive cohort of pediatric ldlt recipients with long-term details of follow-up, although there are several limitations. first, this was a retrospective study conducted at a single medical center. second, the hbv prophylaxis changed from lamivudine to entecavir in 2008, therefore investigators were unable to evaluate the risk of developing lamivudine resistance. in addition, the dna level data for the donor and graft tissues were lacking. lastly, this study was conducted in an area with a high prevalence of anti-hbc positivity.

Eligibility criteria:
inclusion criteria: - consecutive pediatric ldlt recipients. exclusion criteria: * adult ldlt recipients
investigating health related quality of life in patients with chronic respiratory failure

Conditions: Chronic Obstructive Pulmonary Disease; Respiratory Failure; Neuromuscular Diseases; Ventilatory Failure

Summary: to determine the quality of life of patients living with chronic respiratory failure and the impact interventions have on it.

to determine the quality of life of patients living with chronic respiratory failure and the impact interventions have on it.

Eligibility criteria:
inclusion criteria: diagnosed with chronic respiratory failure receiving any of: * non-invasive ventilation * prolonged mechanical ventilation * mechanical insufflation-exsufflation therapy exclusion criteria: * aged \<18 * significant physical or psychiatric co-morbidity that would prevent compliance with trial protocol
suberoylanilide hydroxamic acid in advanced solid tumors

Conditions: Advanced Cancer

Summary: the purpose of this investigational study is to determine the safety and tolerability of oral suberoylanilide hydroxamic acid when administered in combination with standard doses of pemetrexed and cisplatin for the treatment of advanced solid tumors.


Eligibility criteria:
inclusion criteria: * patient must be 18 years or older with confirmed diagnosis of a solid tumor for which pemetrexed and cisplatin is acceptable treatment and have received no more than 2 prior systemic therapies * has at least 1 measurable lesion * has adequate blood, liver, and kidney functions * has not received any chemotherapy for at least 4 weeks prior to entry in this study * agrees to take adequate measures to prevent pregnancy as outlined in the protocol exclusion criteria: * patient has been treated with other investigational agents with a similar anti-tumor mechanism * patient from cohorts a and b has received pemetrexed or cisplatin within the past 6 months and from cohorts c and d have received pemetrexed within the past 6 months * patient from cohorts a and b has preexisting grade 2 or higher neuropathy and from cohorts c and d have grade 3 or higher neuropathy * patient has active infection or had received iv (intravenous) antibiotic, antiviral, or antifungal medications within 2 weeks of the start of study drugs * patient has hiv, hepatitis b or hepatitis c infection * patient is pregnant or breast feeding * patient has allergy to any component of the study drugs * patient has history of gi (gastrointestinal) surgery or conditions

Keywords: advanced solid tumors including mpm and nsclc